Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bapineuzumab in Patients With Mild to Moderate Alzheimer`s Disease (ApoE4 Carrier)

Study:

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer`s Disease Who Are Apolipoprotein E4 Carriers.

Rationale:

n/a

Purpose:

This is a multicenter, double-blind, placebo controlled, randomized, outpatient, multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 200 study sites in the US and Canada will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient`s participation will last approximately 1.5 years. Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly to the patient.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Alzheimer`s Disease Drug: Bapineuzumab 0.5 mg/kg
Drug: Placebo Control
Drug: Bapineuzumab 1.0 m/kg
Phase 3

Verified by JANSSEN Alzheimer Immunotherapy Research & Development, LLC October, 2013

Sponsored by: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Information provided by: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
ClinicalTrials.gov identifier: NCT00575055

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada 89106
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site